ReviewFrontiers in immunology2014
Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.Current hematologic malignancy reports · 2023Review
- Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β.Molecular therapy. Methods & clinical development · 2022Article
- Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors.Regenerative therapy · 2022Article
- Article
- Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.The Journal of clinical investigation · 2022Article
- Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy.Frontiers in immunology · 2022Review
- CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.Stem cell research & therapy · 2021Review
- Review
- Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells.Journal of visualized experiments : JoVE · 2018Article
- Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3Frontiers in immunology · 2018Article
- Engineering Natural Killer Cells for Cancer Immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Review
- CD56 in the Immune System: More Than a Marker for Cytotoxicity?Frontiers in immunology · 2017Review
- Selection and expansion of natural killer cells for NK cell-based immunotherapy.Cancer immunology, immunotherapy : CII · 2016Review
- Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.Oncoimmunology · 2016Article
- A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies.Blood research · 2015Review
- Cellular immunotherapy as a beacon of hope for hematological malignancies.Blood research · 2015Review
- Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.Mucosal immunology · 2015Review
- Immunotherapeutic applications of NK cells.Pharmaceuticals (Basel, Switzerland) · 2015Review
- TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells.Journal of hematology & oncology · 2015Article
- Going back to class I: MHC and immunotherapies for childhood cancer.Pediatric blood & cancer · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blurring the boundary between innate and adaptive immune system, natural killer (NK) cells are widely recognized as potent anti-leukemia mediators. Alloreactive donor NK cells have been shown to improve the outcome of allogeneic stem-cell transplantation for leukemia. In addition, in vivo transfer of NK cells may soon reveal an important therapeutic tool for leukemia, if tolerance to NK-mediated anti-leukemia effects is overcome. This will require, at a minimum, the ex vivo generation of a clinically safe NK cell product containing adequate numbers of NK cells with robust anti-leukemia potential. Ideally, ex vivo generated NK cells should also have similar anti-leukemia potential in different patients, and be easy to obtain for convenient clinical scale-up. Moreover, optimal clinical protocols for NK therapy in leukemia and other cancers are still lacking. These and other issues are being currently addressed by multiple research groups. This review will first describe current laboratory NK cell expansion and differentiation techniques by separately addressing different NK cell sources. Subsequently, it will address the mechanisms known to be responsible for NK cell alloreactivity, as well as their clinical impact in the hematopoietic stem cells transplantation setting. Finally, it will briefly provide insight on past NK-based clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.